---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-029312"
form_type: "8-K"
ticker: "ZVRA"
cik: "0001434647"
company_name: "ZEVRA THERAPEUTICS, INC."
filed_at: "2023-10-30T23:59:59+00:00"
generated_at: "2026-06-09T05:45:51.353024+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Zevra/Acer merger supplement filed; shareholder lawsuits prompt additional disclosures

## Summary
- Three stockholder lawsuits filed (S.D.N.Y. and D. Del.) alleging proxy omissions; demand letters received.
- Acer voluntarily supplements proxy statement on Oct. 30 to address litigation risks, without admitting materiality.
- Supplement adds details: no standstill provisions in confidentiality agreements, no officer/director employment offers from Zevra.
- Updated financial analyses: DCF terminal growth rate of -80%; implied equity values $0.90-$2.71 (Plan 1) and $1.13-$3.63 (Plan 2).
- Acer board continues to unanimously recommend stockholder vote 'FOR' the merger at Nov. 8 special meeting.

## SEC filing metadata
- accession: 0001437749-23-029312
- form_type: 8-K
- ticker: ZVRA
- cik: 0001434647
- company_name: ZEVRA THERAPEUTICS, INC.
- filed_at: 2023-10-30T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434647/000143774923029312/0001437749-23-029312-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434647/000143774923029312/zvra20231027_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-029312
- JSON: https://secwatch.observer/filing/0001437749-23-029312.json
- Plain text: https://secwatch.observer/filing/0001437749-23-029312.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.